Cytori Therapeutics was upgraded by Zacks Investment Research from a "hold" rating to a "buy" rating, according to the Daily Political.
Here are five insights:
1. The brokerage presently has a $0.25 price objective on the stock.
2. Zacks Investment Research's price target would indicate a potential upside of 34.41 percent from the stock's current price.
3. Cytori Therapeutics discovers and develops proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue.
4. The company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery.
5. Cytori developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will improve the speed in which personalized cell-based therapies can be delivered to patients.